Sivik Global Healthcare LLC Invests $1.71 Million in BioNTech SE (NASDAQ:BNTX)

Sivik Global Healthcare LLC purchased a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,000 shares of the company's stock, valued at approximately $1,709,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Marshall Wace LLP purchased a new stake in shares of BioNTech during the 2nd quarter valued at $2,892,000. Sanctuary Advisors LLC bought a new position in shares of BioNTech in the second quarter valued at approximately $223,000. GAMMA Investing LLC grew its position in shares of BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after purchasing an additional 111 shares in the last quarter. Atomi Financial Group Inc. purchased a new position in BioNTech during the third quarter worth about $405,000. Finally, Perfromance Wealth Partners LLC purchased a new position in shares of BioNTech during the third quarter worth about $238,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

Shares of BNTX stock traded down $3.95 during trading hours on Monday, reaching $119.82. The company had a trading volume of 591,928 shares, compared to its average volume of 741,554. The firm has a market cap of $28.73 billion, a PE ratio of -57.04 and a beta of 0.17. The business has a fifty day moving average price of $117.34 and a 200-day moving average price of $107.33. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.73 EPS. Sell-side analysts predict that BioNTech SE will post -3.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on BNTX shares. HSBC increased their target price on BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a research note on Monday, October 7th. HC Wainwright reiterated a "buy" rating and set a $150.00 price target on shares of BioNTech in a report on Monday, November 18th. Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective for the company. Canaccord Genuity Group lifted their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a research note on Wednesday, November 27th. Finally, TD Cowen dropped their price target on BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research report on Tuesday, November 5th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.